ERBB2 and breast carcinoma: Besides, our meta-analysis was the first to provide substantial evidence for the beneficial effect of trastuzumab in HER2-positive pT1a-bN0M0 women with regard to DFS, which suggests that similar strategy for the targeted therapy of HER2-positive breast cancer might also be apt for such patients.